ImmunoPrecise Antibodies Ltd. (HYFT)vsMerck & Company Inc (MRK)
HYFT
ImmunoPrecise Antibodies Ltd.
$1.20
+1.69%
HEALTHCARE · Cap: $56.53M
MRK
Merck & Company Inc
$146.35
+3.83%
HEALTHCARE · Cap: $360.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 410035% more annual revenue ($66.57B vs $16.23M). MRK leads profitability with a 4.8% profit margin vs -105.2%. MRK earns a higher WallStSmart Score of 36/100 (F).
HYFT
Avoid24
out of 100
Grade: F
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HYFT.
Margin of Safety
-73.7%
Fair Value
$83.64
Current Price
$146.35
$62.71 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 21.3% year-over-year
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Trading at 12.0x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -81.3% — below average capital efficiency
Trading at 8.6x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : HYFT
The strongest argument for HYFT centers on Revenue Growth. Revenue growth of 21.3% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : HYFT
The primary concerns for HYFT are Price/Book, EPS Growth, Market Cap.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 115.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
HYFT profiles as a growth stock while MRK is a value play — different risk/reward profiles.
HYFT carries more volatility with a beta of 0.78 — expect wider price swings.
HYFT is growing revenue faster at 21.3% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (36/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ImmunoPrecise Antibodies Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
MindWalk Holdings Corp. The company is headquartered in Austin, Texas.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?